Sweeteners and liver disease – summary
- Sweeteners are found in thousands of food and drink products
- Scientists link sweeteners to cardiovascular, metabolic, neurological, and developmental concerns
- New research flags sorbitol metabolism behaving similarly to fructose
- Study associates sorbitol with fatty liver disease mechanisms progression
- Manufacturers face rising consumer scepticism, regulatory risk, and reformulation pressure
From sweets and cakes to spreads, sauces and ready meals, sweeteners are used in thousands of food and beverage products worldwide.
Whether it’s to cut sugar levels, enhance flavour, balance acidity, refine texture, improve mouthfeel or extend shelf life, they play a crucial role in shaping the sensory experience, and overall performance of today’s food and drink.
But, while manufacturers celebrate sweeteners as the perfect solution to many production challenges, scientists urge caution.
In recent years, we’ve seen xylitol linked to an increased risk of heart attack and stroke, neotame linked to gut damage, sucralose linked to increased appetite, and multiple sweeteners linked to cognitive decline.
It’s little wonder then that many consumers are moving away from products containing them.
And matters are getting worse as new research has found links between a commonly-used sweetener and liver disease.
Do sweeteners cause liver disease?
Scientists at Washington University in St Louis are raising concerns around popular sweetener, sorbitol.
Their research suggests the sugar alcohol within sorbitol can trigger processes linked to fatty liver disease.
The study, published in Science Signaling, found that sorbitol behaves similarly to fructose once inside the body.
“The most surprising finding from the current work is that because sorbitol is essentially ‘one transformation away from fructose’ it can induce similar effects,” says senior author Gary Patti, professor at Washington University.
Fructose has already been linked with metabolic dysfunction–associated steatotic liver disease (MASLD), a condition formerly known as fatty liver disease. MASLD now affects an estimated 30% of adults globally and is increasingly being diagnosed in younger people.
Patti’s lab has spent years studying fructose metabolism and its effects on disease, with previous research revealing that fructose processing in the liver can be hijacked by cancer cells to fuel growth.
A separate study in lactating rats found that maternal sorbitol consumption caused metabolic abnormalities, liver damage markers, DNA damage, and impaired growth in offspring
The researchers emphasise that there’s no cause for immediate alarm surrounding the consumption of sorbitol, highlighting that the experiments involved concentrated exposure to the sweetener. The research was also conducted on fish rather than humans. Though the results challenge a long-standing assumption that sugar alcohols pass through the body without major consequences.
“We do absolutely see that sorbitol given to animals ends up in tissues all over the body,” says Patti.
The researchers say more studies are needed to determine whether similar mechanisms occur in humans.
What does this mean for manufacturers?
For manufacturers, the potential health implications of sweeteners are becoming harder to ignore.
They may remain a powerful formulation tool, but the growing body of scientific scrutiny is shifting the risk profile around their use. What was once seen primarily as a technical or regulatory challenge is increasingly a reputational one, as consumers question not just sugar levels, but the broader health impact of the ingredients used to replace it.
This puts food and drinks companies in a difficult position. On the one hand, reformulation pressures such as sugar taxes and calorie reduction targets, show no signs of easing. And on the other, reliance on familiar sweeteners may expose brands to consumer backlash, negative headlines and, potentially, tighter regulatory oversight if emerging research continues to raise red flags.
As a result, manufacturers may need to rethink their long-term sweetening strategies. That could mean reducing overall sweetness, investing in alternative ingredients with stronger safety narratives, or taking a more transparent approach to formulation and communication. It may also require closer engagement with the scientific community to ensure innovation keeps pace with evolving evidence.
